Anti-osteoporotic activity of puerarin 6″-O-xyloside on ovariectomized mice and its potential mechanism

Figures & data

Figure 1. Chemical structure of puerarin 6″-O-xyloside (PXY).

Figure 2. Effects of PXY body on weight and uterine weight of OVX mice. Each column represented as mean ± standard deviation (n = 10). The vehicle (10 ml/kg) and PXY (20, 40, and 60 mg/kg) were administered intraperitoneally. #p < 0.05, ##p < 0.01, compared with the sham group; *p < 0.05, **p < 0.01, compared with the OVX group.

Figure 3. Effects of PXY on body blood calcium and blood phosphorus contents of OVX mice. Each column represented as mean ± standard deviation (n = 10). The vehicle (10 ml/kg) and PXY (20, 40, and 60 mg/kg) were administered intraperitoneally. ##p < 0.01, compared with the sham group; *p < 0.05, **p < 0.01, compared with the OVX group.

Figure 4. Effects of PXY on ALP and OPG contents of OVX mice. Each column represented as mean ± standard deviation (n = 10). The vehicle (10 ml/kg) and PXY (20, 40, and 60 mg/kg) were administered intraperitoneally. #p < 0.05, ##p < 0.01, compared with the sham group; *p < 0.05, **p < 0.01, compared with the OVX group.

Figure 5. Effect of PXY on femur osseous tissue in ovariectomized mice. (A–E) The Sham, ovariectomized model, and PXY treatment (20, 40, and 60 mg/kg) are represented, respectively. The vehicle (10 ml/kg) and PXY were administered intraperitoneally.

Table 1. Effects of PXY on the proliferation of osteoblasts.

	OD550
	24 h	48 h	72 h
Control
	0.32 ± 0.04	0.47 ± 0.06	0.67 ± 0.09
5 μM	0.38 ± 0.05*	0.56 ± 0.08*	0.84 ± 0.12**
PXY
10 μM	0.43 ± 0.05*	0.61 ± 0.09**	0.89 ± 0.15**
20 μM	0.46 ± 0.06*	0.67 ± 0.10**	0.91 ± 0.14**

Effects of PXY on the proliferation of osteoblasts. Cells were treated with PXY treatment (5, 10, and 20 μM) for 24, 48, and 72 h, respectively. Data were presented as mean ± standard deviation (n = 4).

*p < 0.05, **p < 0.01, compared with control.

Figure 6. Effect of PXY on expressions of OPG and RANKL in osteoblasts. Osteoblastic cells from neonatal rat calvarias were treated with PXY treatment (5, 10, and 20 μM) for 48 h. Protein expressions of OPG and RANKL were determined by western blotting, and β-actin was used as an internal reference. Data were presented as mean ± standard deviation (n = 4), **p < 0.01, compared with control.